Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing and precision medicine, today announced the publication of more than 300 peer-reviewed papers featuring its technology and reinforcing its long-standing commitment to robust clinical evidence and scientific research.
These publications span high-impact journals – such as Nature, Nature Medicine, the American Journal of Transplantation and American Journal of Obstetrics and Gynecology – and highlight breakthroughs such as earlier detection of disease and improved clinical decision-making.
This milestone includes:
- Over 150 publications featuring Natera’s oncology portfolio, with more than 140 focused on the utility of Signatera™ across multiple types of cancer.
- More than 100 publications on its Women’s Health technologies, showcasing robust datasets on non-invasive prenatal testing, carrier screening and other applications.
- Over 60 publications related to its Organ Health solutions, with significant evidence across heart, kidney and lung transplantation.
“Reaching 300 peer-reviewed publications is a powerful testament to the depth of our scientific investment and the value our technology brings to patients,” said Minetta Liu, M.D., chief medical officer for oncology at Natera. “These data demonstrate our commitment to improving clinical care across disciplines. We are grateful to our research collaborators and the many patients who make this work possible.”